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Human pluripotent stem cells (hPSCs) offer a unique
platform for elucidating the genes and molecular
pathways that underlie complex traits and dis-
eases. To realize this promise, methods for rapid
and controllable genetic manipulations are urgently
needed. By combining two newly developed gene-
editing tools, the TALEN and CRISPR/Cas systems,
we have developed a genome-engineering platform
in hPSCs, which we named iCRISPR. iCRISPR
enabled rapid and highly efficient generation of bial-
lelic knockout hPSCs for loss-of-function studies,
as well as homozygous knockin hPSCs with specific
nucleotide alterations for precise modeling of dis-
ease conditions. We further demonstrate efficient
one-step generation of double- and triple-gene
knockout hPSC lines, aswell as stage-specific induc-
ible gene knockout during hPSC differentiation. Thus
the iCRISPRplatform is uniquely suited for dissection
of complex genetic interactions and pleiotropic gene
functions in human disease studies and has the po-
tential to support high-throughput genetic analysis
in hPSCs.
INTRODUCTION
The identification and functional validation of sequence variants
affecting diverse human traits, including disease susceptibility, is
key to understanding human biology and disease mechanisms.
Advances in next-generation sequencing and genome-wide as-
sociation studies have led to the rapid discovery of numerous
disease-associated sequence variants in recent years. To func-
tionally validate this increasing number of disease-associated
mutations, an ideal platform should not only closely recapitulate
their genomic, cellular, and human-specific contexts (Cooper
and Shendure, 2011), but also offer superior speed and capacity
to meet the growing demand.CHuman pluripotent stem cells (hPSCs), including human em-
bryonic stem cells (hESCs) and the closely related human
induced pluripotent stem cells (hiPSCs), offer a promising solu-
tion to meet these challenges (Zhu and Huangfu, 2013). First,
hPSCs have unlimited self-renewal capacity, providing a renew-
able source of experimental cells suitable for rapid, large-scale
analyses. Second, they have the potential to generate all adult
cell types, including rare or inaccessible human cell populations,
providing a unique platform to recapitulate the cellular and hu-
man-specific contexts required for disease studies. Yet, to fulfill
this potential, it is of paramount importance to develop methods
for rapid, efficient, and controllable genetic manipulation in
hPSCs. Unfortunately, while classic gene-targeting technology
via homologous recombination in mouse ESCs (mESCs) has
proven a powerful tool to dissect gene function (Capecchi,
2005; Thomas and Capecchi, 1986; Thomas et al., 1986), this
approach has been extremely inefficient when applied to hPSCs
(Hockemeyer and Jaenisch, 2010).
Recently, with the advent of programmable site-specific nu-
cleases, genome engineering has become a much easier task
in a wide range of organisms and cultured cell types including
hPSCs (Joung and Sander, 2013; Ran et al., 2013b; Urnov
et al., 2010). Acting as ‘‘DNA scissors,’’ they induce double
strand breaks (DSBs) at desired genomic loci, triggering the
endogenous DNA repair machinery. Processing of DSBs by
the error-prone nonhomologous end-joining (NHEJ) pathway
leads to small insertions and deletions (Indels) useful for gener-
ating loss-of-function mutations, whereas error-free homology
directed repair (HDR) enables targeted integration of exoge-
nously provided DNA sequences for introducing precise nucleo-
tide (nt) alterations or knockin reporters.
Transcription activator-like effector nucleases (TALENs) and
the clustered regularly interspaced short palindromic repeats
(CRISPR)/CRISPR-associated (Cas) systems have emerged
as powerful and versatile site-specific nucleases for genome
modification in a variety of model systems. TALENs are typically
designed as pairs to bind the genomic sequences flanking
the target site. Each TALEN arm consists of a programmable,
sequence-specific TALE DNA-binding domain linked to a
nonspecific DNA cleavage domain derived from the bacterial
restriction endonuclease FokI (Cermak et al., 2011; Millerell Stem Cell 15, 215–226, August 7, 2014 ª2014 Elsevier Inc. 215
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the prokaryotic type II CRISPR/Cas system for genome editing
in eukaryotic systems (Cong et al., 2013; DiCarlo et al., 2013;
Gratz et al., 2013; Hwang et al., 2013; Mali et al., 2013b).
The type II CRISPR/Cas system requires two components:
the DNA endonuclease Cas9 protein for DNA cleavage and
a variable CRISPR RNA (crRNA) and trans-activating crRNA
(tracrRNA) duplex for DNA target recognition (Jinek et al.,
2012). Binding of crRNA/tracrRNA to the target sequence via
Watson-Crick base pairing directs Cas9 to any genomic locus
of interest for site-specific DNA cleavage. The CRISPR/Cas
system has now been further improved for use in mammalian
systems through Cas9 codon optimization and replacement of
the crRNA/tracrRNA duplex with a single chimeric guide RNA
(gRNA) (Cho et al., 2013; Cong et al., 2013; Jinek et al., 2013;
Mali et al., 2013b).
While programmable site-specific nucleases have significantly
improved our capacity to genetically modify hPSCs (Ding et al.,
2013a, 2013b; Hockemeyer et al., 2009, 2011; Hsu et al., 2013;
Mali et al., 2013b; Soldner et al., 2011), none of the available
methods has achieved multiplexed gene targeting or inducible
gene knockout in hPSCs. These two features are crucial for inter-
rogating complex genetic interactions and pleiotropic gene func-
tions, which are often difficult to study using animal models due
to the involvement of multiple alleles and random segregation of
these alleles through breeding.
To achieve rapid, multiplexable, and inducible genome editing
in hPSCs, we have developed a genome-engineering platform.
Through TALEN-mediated gene targeting, we created a panel
of hPSC lines for robust, doxycycline-inducible expression of
Cas9 (referred to as iCas9 hPSCs). By transfecting iCas9 hPSCs
with gRNAs targeting different genes, we have generated bial-
lelic knockout hPSC lines for six individual genes with high effi-
ciency (20% to 60%). This highly efficient platform enabled
us to generate double- and triple-gene knockout hPSC lines in
a single step with up to 10% efficiency. Moreover, cotransfec-
tion of gRNAs with a single-stranded DNA (ssDNA) HDR tem-
plate yielded homozygous knockin clones at a rate of up to
10%, allowing efficient and scarless introduction of defined
nucleotide modifications in different hPSC lines for disease
modeling. Finally, we achieved stage-specific inducible gene
knockout during hPSC differentiation. This versatile new plat-
form, which we called ‘‘iCRISPR,’’ allows rapid generation of
mutant hPSCs for analysis of complex disease phenotypes in
isogenic backgrounds and could be easily scalable for high-
throughput genetic analysis.
RESULTS
An iCRISPR Platform for Rapid and Versatile Genome
Editing
A recent study by Jaenisch and colleagues successfully applied
CRISPR/Cas for highly efficient genomemodifications in mESCs
(Wang et al., 2013), which suggests similar approaches may
work in hPSCs. Encouraged by these findings, we investigated
the efficiency of CRISPR/Cas-mediated genome editing in
hESCs through plasmid electroporation to transiently express
Cas9 and a specific gRNA, a method that is currently used
in hESCs (Figure 1A, upper panel). Although we successfully216 Cell Stem Cell 15, 215–226, August 7, 2014 ª2014 Elsevier Inc.generated heterozygous GATA6 mutant lines at 2%–6% effi-
ciencies, no homozygousmutants were identified out of 384 total
hESC clones analyzed (Table 1). This finding is consistent with
the variable and generally low gene editing efficiencies observed
by others in hPSCs (Ding et al., 2013b; Hsu et al., 2013; Mali
et al., 2013b) and highlights the need for a more efficient method
to model human traits caused by recessive or multiple-gene
mutations.
We reasoned that one could develop a more efficient and ver-
satile genome-editing platform by first generating hPSCs that
expressCas9, the invariable component of theCRISPR/Cas sys-
tem. We anticipated that Cas9-expressing hPSCs would be
easily transfected with gRNAs due to their small size (100 nt),
which in turn could lead to reproducible and highly efficient
genome editing (Figure 1A, lower panel). We first determined
the efficiency of lipid-mediated transfection of small RNAs.
Using a control fluorescence-labeled, double-stranded RNA
(dsRNA) probe, we estimated that60% hESCs would be trans-
fected with gRNAs (Figure S1A available online). In contrast, only
10% GFP+ hESCs were detected by flow cytometry after elec-
troporation of a GFP-expressing plasmid of comparable size
with the Cas9/gRNA vectors (Figures S1A–S1D). Importantly
and in contrast to plasmid electroporation, lipid-mediated trans-
fection is associated with very low cytotoxicity. This opens up
the possibility of repeated transfections and cotransfection of
multiple gRNAs for multiplexed genome editing, as well as
gRNA transfection during a specific stage of hPSC differentiation
for inducible gene knockout.
We next engineered iCas9 hPSC lines for doxycycline-induc-
ible expression of Cas9 through TALEN-mediated gene target-
ing. We chose to target the transgenes into the AAVS1 (also
known as PPP1R12C) locus because it has been shown to
support robust and sustained transgene expression in a
manner similar to that of the Rosa26 locus in mice (Smith
et al., 2008). Based on a gene trap approach used by Jaenisch
and colleagues (Hockemeyer et al., 2011), we coelectropo-
rated the AAVS1 TALEN constructs with two donor plasmids
targeting the first intron of the PPP1R12C gene in three
hESC lines (HUES8, HUES9, and MEL-1) and one hiPSC line
(BJ iPSC) (Cowan et al., 2004; Huangfu et al., 2008). One donor
plasmid contains a doxycycline-inducible Cas9 expression
cassette (Puro-Cas9 donor), and the other carries a constitu-
tive reverse tetracycline transactivator (M2rtTA) expression
cassette (Neo-M2rtTA donor) (Figures 1B, S1E, and S1F).
Southern blot analysis revealed a high biallelic targeting effi-
ciency: >50% of the clonal lines have both transgenes
correctly inserted without additional random integrations (Fig-
ures 1C and S1G). qRT-PCR analysis confirmed the induction
of Cas9 expression upon doxycycline treatment in all clonal
iCas9 lines examined (Figures 1D and S1H). Further analysis
showed that iCas9 hPSCs display uniform expression of the
pluripotency markers OCT4, NANOG, and SOX2 (Figure S1I)
and maintain the capacity to differentiate into tissue derivatives
of the three embryonic germ layers in teratoma assays (Fig-
ure S1J). Furthermore, the AAVS1 targeting strategy does not
introduce apparent chromosomal aberrations, as confirmed
by karyotyping analysis (two of the iCas9 lines inherited a
duplication present in the parental line before the targeting
experiment) (Table S1).
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Figure 1. Engineering an iCRISPR Platform
through Generating iCas9 hPSCs
(A) Schematic comparison of the current genome
editing approach in hPSCs by electroporation of
a 10 kilobase (kb) CRISPR/Cas9 vector (upper
panel) with the iCRISPR platform (lower panel) for
genome editing in hPSCs. Cas9 protein (green)
binds a chimeric gRNA composed of a constant
transactivating structural region (purple) and a
variable DNA recognition site (red). The Cas9/
gRNA complex binds to DNA and induces a
DSB (yellow). TRE, tetracycline response element;
CAG, constitutive synthetic promoter; M2rtTA,
reverse tetracycline transactivator sequence and
protein; doxycycline, red dots.
(B) Generation of iCas9 hPSCs through TALEN-
mediated gene targeting at the AAVS1 locus. Red
lines indicate homology to PPP1R12C intron 1; SA,
splice acceptor; 2A, self-cleaving 2A peptide;
Puro, Puromycin resistance gene; Neo, Neomycin
resistance gene.
(C) Southern blot analysis of HUES8 iCas9 lines
using 30 external and 50 internal probes. Lines
carrying desired targeted insertions of the Puro-
Cas9 and Neo-M2rtTA donor sequences without
random integrations are indicated in red.
(D) Quantitative real-time RT-PCR (qRT-PCR)
analysis of Cas9 transcript levels with or without
doxycycline (Dox) treatment in HUES8 iCas9 lines.
See also Figure S1 and Table S1.
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Knockout hPSCs
To determine the capacity of iCas9 hPSCs for gene editing,
we designed a panel of gRNAs targeting six genes (NGN3,
GATA4,GATA6, TET1, TET2, and TET3) located on five different
chromosomes (Figure S2A). We first selected gRNAs effectively
targeting each gene by performing experiments in 293T cells and
assessing Indel rates using T7 Endonuclease I (T7EI), which
specifically cleaves heteroduplexes formed by the hybridization
of wild-type and mutant DNA sequences (Mashal et al., 1995)Cell Stem Cell 15, 215–22(Figure S2B). Next, iCas9 hPSCs were
treated with doxycycline and transfected
with selected gRNAs generated through
in vitro transcription (Figure 2A). We
observed 30% Indel rates based on
T7EI assays performed on genomic
DNA extracted 2 or 3 days after gRNA
transfection (Figure 2B). For TET1 and
TET2, we designed Restriction Fragment
Length Polymorphism (RFLP) assays
to directly assess the loss of a restric-
tion site in proximity to the predicted
Cas9 cleavage site (Figure 2C). RFLP
assays revealed a higher mutation rate
compared to T7EI (42% versus 26% for
TET1-Cr2, 42% versus 31% for TET2-
Cr4; Figure 2D), suggesting that T7EI
assays may underestimate the rate of
mutations as suggested for similar Indel
assays (Guschin et al., 2010). Encour-aged by these high Indel rates, we then performed multiplexed
genome editing through cotransfection of gRNAs targeting
two or three genomic loci. Multiplexed targeting of GATA4 and
GATA6 induced 28% and 16% of Indels in the respective loci
(Figure 2E). Similar efficiencies were observed for multiplexed
targeting of TET1, TET2, and TET3 (to 17%, 11%, and 18%,
respectively) through optimizing the transfection conditions
(Figure 2E and Figures S3A–S3D). These results suggest
that our system supports efficient genome editing including
multiplexing.6, August 7, 2014 ª2014 Elsevier Inc. 217
Table 1. CRISPR/Cas-Mediated Single-Gene Targeting in hESCs
Gene CRISPR Delivery Method
Mutant Alleles per Clone
1
2
compound heterozygotes homozygotes total biallelic mutant clones
NGN3 Cr5 gRNA transfection 2/48 (4.2%) 2/48 10/48 12/48 (25%)
Cr6 gRNA transfection 1/36 (2.8%) 1/36 5/36 6/36 (16.7%)
GATA4 Cr2 gRNA transfection 2/96 (2.1%) 19/96 5/96 24/96 (25%)
GATA6 Cr1 gRNA transfection 14/40 (35%) 7/40 0/40 7/40 (17.5%)
Cr8 gRNA transfection 6/48 (12.5%) 13/48 1/48 14/48 (29.2%)
Cr8 plasmid electroporation 2/96 (2.1%) 0/96 0/96 0/96 (0%)
Cr8 plasmid electroporation* 17/288 (5.9%) 0/288 0/288 0/288 (0%)
TET1 Cr2 gRNA transfection 4/48 (8.3%) 10/48 3/48 13/48 (27.1%)
TET2 Cr4 gRNA transfection 6/48 (12.5%) 14/48 14/48 28/48 (58.3%)
TET3 Cr4 gRNA transfection 4/48 (8.3%) 24/48 8/48 32/48 (66.6%)
In vitro transcribed gRNAs targeting NGN3, GATA4, GATA6, NGN3, TET1, TET2, or TET3 were transfected in doxycycline-induced iCas9 hESCs or
electroporated as plasmids (GATA6 Cr8) in wild-type HUES8 or HUES9 (*) hESCs. The number of lines containing each specific number of mutated
alleles (1 or 2) is shown in relation to the total number of lines screened in each experiment.
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ure 3A). For single-gene targeting, we generated mutant hESC
lines affecting six individual genes after typically sequencing 36
to 96 clones for each targeting experiment. Approximately
42% (ranging from 20% to 75%) clones carried mutations in at
least one allele. Notably, the majority of mutant clones carried
mutations in both alleles, including both homozygous and com-
pound heterozygous mutations (Figures 3B and 3D and Table 1).
Some gRNAs induced nonrandom deletions on target se-
quences in a significant number of clones, a phenomenon which
has been reported by others in the murine system (Wang et al.,
2013). For instance, 10 out of 12 biallelic mutant lines generated
with an NGN3-targeting gRNA (NGN3-Cr6) contained an
identical homozygous 7 base pair (bp) deletion, and 9 out of 14
biallelic mutant clones generated with a TET2- targeting gRNA
(TET2-Cr2) carried the same 3 bp deletion (Figure S3E). Prefer-
ential generation of these alleles is likely caused by microhomol-
ogy-mediated repair that utilizes short stretches of repeated
sequences flanking the DSB site.
The use of iCas9 hPSCs also enabled efficient one-step multi-
plexed gene editing. We were able to identify mutant clones
affecting two genes (i.e., all four alleles of GATA4 and GATA6)
and three genes (i.e., all six alleles of TET1, TET2, and TET3)
with5% efficiencies (Figures 3C and 3D and Table S2). Further
optimization of gRNA transfection conditions (Figures S3A–S3D)
improved the efficiency of biallelic triple-gene targeting to close
to 10% (Table S2). Since TET proteins are responsible for cata-
lyzing the conversion of 5-methylcytosine (5mC) to 5-hydroxy-
methylcytosine (5hmC) (Ito et al., 2010; Tahiliani et al., 2009),
we analyzed the 5hmC levels in triple-targeted hESC lines. As
expected from loss-of-function alleles, we detected a significant
reduction of 5hmC levels in all triple-genemutant lines compared
with wild-type control hESCs (Figure 3E). These findings demon-
strate rapid, single-step generation of multiple-gene knockout
lines for loss-of-function studies. Importantly, despite the high
gene-editing efficiencies, we did not detect off-target mutations
in multiple single- and triple-gene mutant hESC lines analyzed
(Table S3).218 Cell Stem Cell 15, 215–226, August 7, 2014 ª2014 Elsevier Inc.Precise HDR-Mediated Genome Editing for Disease
Modeling
To accurately dissect gene function in human development and
disease, precise nucleotide alterations are required to either
create disease-specific variants in wild-type cells or correct dis-
ease-associated mutations in patient cells. To test this
approach, we cotransfected doxycycline-treated iCas9 hPSCs
with a GATA6-targeting gRNA (GATA6-Cr8) and a 110 nt ssDNA
repair template introducing a single nt mutation (Figures 4A and
4B). T7EI analysis revealed 50% and 35% mutation rates in
HUES8 and BJ iPSCs, respectively. Because the HDR ssDNA
template creates a silent BsgI restriction site in GATA6, we
next performed RFLP analysis to discriminate successful HDR-
mediated gene editing from NHEJ-mediated Indels, and we
determined that 15% of HUES8 and8% of BJ iPSC genomic
DNA sequences integrated the desired modification (Figures 4C
and 4D). Next, we replated transfected cells to establish mutant
clones (Figure 4B). RFLP analysis on 96 clones identified 33
(34%) cloneswith at least one BsgI site and 15 (16%) clones con-
taining one BsgI site in each GATA6 allele (Figure 4E). Sequence
analysis verified that nine clones carried the desired homozy-
gous mutations without additional sequence alterations (Figures
4F and 4G). Similar results were obtainedwith theNGN3 locus as
determined by RFLP analysis (Figures S4A and S4B).
Since our platform allows rapid generation of precise homozy-
gous knockin mutations, we tested the feasibility of generating
an allelic series for modeling disease susceptibility.
APOE is the most common risk locus associated with late-
onset Alzheimer’s disease (LOAD). There are three common
allelic variants of APOE, known as ε2, ε3, and ε4. The most com-
mon ε3 variant is considered ‘‘neutral,’’ whereas the ε4 variant is
the major known risk factor with a dose-dependent effect: an
increased number of the ε4 alleles (i.e., from 0 to 1 and to 2) is
associated with increased risk and decreased onset age (Corder
et al., 1993). Sequence analysis showed that bothHUES8 andBJ
iPSCs carry the common ε3/ε3 genotype (Figure 5A). We there-
fore sought to create hPSCs carrying the ε3/ε4 and ε4/ε4 geno-
types, which would be useful for modeling disease susceptibility.
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Figure 2. Single and Multiplexed gRNA
Transfection Efficiently Induces Indels in
iCas9 hPSCs
(A) Schematic representation of the experimental
procedure.
(B) T7EI assay for Cas9-mediated cleavage in
HUES8 iCas9 cells using single gRNAs targeting
NGN3 (Cr5, 6),GATA6 (Cr1, 8), TET1 (Cr2, 3), TET2
(Cr3, 4), and TET3 (Cr2, 4). All gRNAs were trans-
fected twice, except for GATA6 (Cr1, 8), which
were transfected once. In all figures in this study
red asterisks indicate the expected T7EI-specific
fragments used to quantify Indel frequency (blue).
(C) Schematic of Cas9/gRNA-targeting sites (pink
arrows in all figures in this study) in TET1 and TET2
loci showing exon structure (blue boxes in all
figures in this study), PCR amplicons (light gray
boxes in all figures in this study), and StyI or PstI
restriction sites used for RFLP analysis. gRNA-
targeting sequences are in bold; protospacer-
adjacent motif (PAM) sequences are in orange;
Cas9 cleavage sites are indicated by blue arrow
heads; and restriction sites are underlined, here
and in all figures in this study.
(D) RFLP analysis upon TET1 (Cr2, 3), TET2 (Cr3,
4), or multiplexed TET1, 2, 3 (Triple) gRNA trans-
fection. In all figures in this study green asterisks
indicate the uncut PCR fragment used to quantify
Indel frequency by RFLP (blue).
(E) T7EI assay in HUES8 iCas9 cells transfected
with multiplexed GATA4, 6 (Double) or TET1, 2, 3
(Triple) gRNAs.
See also Figure S2.
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rs429358 in APOE exon 4 to introduce a T-to-C transition for
conversion from ε3 to ε4 (Figure 5B).We designed gRNAs target-
ing APOE (Figure S4C) and selected the most effective one
(APOE-Cr3) through the T7EI assay (Figure S4D). Next, we co-
transfected doxycycline-treated iCas9 hPSCs with APOE-Cr3
gRNA and a 120 nt ssDNA repair template carrying the ε4 poly-
morphism and a BanI silent restriction site (Figure 5B). T7EI anal-
ysis revealed21% and13%mutation rates in the HUES8 and
BJ iPSC APOE loci, respectively. As observed previously, RFLP
assay using NotI revealed a higher mutation rate (49% in HUES8
and 23% in BJ iPSCs; Figures 5C and 5D). Using BanI RFLP we
further discriminated HDR-mediated gene editing from NHEJ-
mediated Indels and estimated that 2%–3% of the target
sequence had the desired modification (Figures 5C and 5D).
Indeed, sequence analysis confirmed successful generation of
clonal lines carrying an APOE allelic series in both HUES8 and
BJ iPSCs: the original ε3/ε3 and the modified ε3/ε4 and ε4/ε4
genotypes (Figure 5A). This strategy could be easily modified
to convert the risk-associated ε4 variant to the standard ε3
variant to create isogenic control cells for studies of hPSCs
carrying the ε4 variant or for therapeutic purposes.Cell Stem Cell 15, 215–22Inducible Gene Knockout
Inactivating genes in a temporal or tissue-
specific manner has greatly facilitated the
study of genes with pleiotropic effects.
Since the iCRISPR platform allows induc-ible Cas9 expression and tightly regulated delivery of gRNA with
minimal toxicity, we investigated the feasibility of conducting
inducible gene knockout. We were able to differentiate iCas9
hESCs first into definitive endoderm (DE) and subsequently
into pancreatic progenitor (PP) and insulin-expressing b-like
cells based on an established protocol (Kroon et al., 2008) (Fig-
ures S5A and S5B). We proceeded to determine the efficiencies
of inducible knockout by inducing Cas9 expression and perform-
ing gRNA transfection at the PP stage (Figure 6A). T7EI analysis
revealed an 20% Indel rate in PP cells transfected with an
NGN3-targeting gRNA (NGN3-Cr6) (Figure 6B). To further inves-
tigate the feasibility of using iCas9 cells for knocking out genes
in a tissue-specific manner, we enriched CXCR4-expressing
DE cells through fluorescence-activated cell sorting (FACS)
(D’Amour et al., 2005) and differentiated the cells further to
the PP stage for gRNA transfection (Figure 6A). T7EI analysis
showed that PP cells transfected with single gRNAs targeting
different genes carried on average30% Indels in optimal trans-
fection conditions (Figure 6C). As observed in other experiments,
RFLP assays detected higher Indel rates, around 60% with
gRNAs targeting TET1 and TET2 (Figure 6D). Sequencing anal-
ysis of the PCR amplicon clones, a more direct measurement6, August 7, 2014 ª2014 Elsevier Inc. 219
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GATA4+GATA6 double KO
TET1+TET2+TET3 triple KO
TET1, 2, 3 triple mutant hESC lines
Figure 3. Single and Multiplexed Gene
Targeting
(A) Strategy of gene targeting.
(B and C) Allelic sequence distribution in HUES8
clonal lines generated with single gRNAs targeting
NGN3 (Cr5, 6),GATA4 (Cr2),GATA6 (Cr1, 8), TET1
(Cr2), TET2 (Cr4), or TET3 (Cr4) (B), or multiplexed
gRNAs targetingGATA4 andGATA6 (Cr2 and Cr1,
respectively) or TET1, TET2, and TET3 (Cr2, Cr4,
and Cr4, respectively) (C).
(D) Representative sequences of various knockout
(KO) mutant clones with PAM sequences labeled
in orange. pm, point mutation.
(E) Analysis of 5hmC levels in DNA isolated from
TET1, 2, 3 triple-targeted hESC clones by dot
blot assay using an anti-5hmC antibody. Wild-type
HUES8 iCas9 cells and human foreskin fibroblasts
(HFFs) were used as controls.
See also Figure S3 and Tables S2 and S3.
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for all targeting experiments, reaching up to 97% with TET3
(Figure 6E). Notably, the majority of mutations were frameshift,
supporting the usage of this inducible gene-editing approach
for examination of loss-of-function phenotypes in a temporal-
specific and cell-type-specific manner.
The gRNA transfection method described above may interfere
with some differentiation procedures. To overcome this limita-
tion, we generated a Puro-Cr donor by modifying the Puro-
Cas9 AAVS1 donor vector to include a constitutive gRNA
expression module in addition to the doxycycline-inducible
Cas9 expression cassette (Figure S5C). Coelectroporation
of this Puro-Cr donor with the Neo-M2rtTA donor and the220 Cell Stem Cell 15, 215–226, August 7, 2014 ª2014 Elsevier Inc.AAVS1-TALEN constructs allows the
generation of hPSC lines for conve-
nient, inducible knockout studies: all
cells would express the gRNA of inter-
est, which, upon doxycycline treatment,
would target the induced Cas9 protein
to the desired genomic locus (Figure 6F).
Following this strategy, we generated
hESC lines for inducible knockout
of NGN3 and TET2, named iCrNGN3
and iCrTET2, respectively (Figure S5D).
Doxycycline treatment of differentiated
iCrNGN3 and iCrTET2 hESCs at the PP
stage resulted in consistent induction of
Indels as revealed by T7EI and RFLP as-
says (Figures 5G and 5H). Sequencing
analysis of the PCR amplicons revealed
55% and 75% mutation rates in
induced iCrNGN3 and iCrTET2 hESCs
(Figure 6I). The ratio of frameshift versus
nonframeshift mutations differed signifi-
cantly between induced iCrNGN3 and
iCrTET2 hESCs, suggesting that the
knockout efficiencies also depend on
the types of mutations generated. Impor-
tantly, to determine the tightness of ourinducible system, we analyzed PCR amplicons after prolonged
in vitro culture of iCrNGN3 hESCs (15 passages after establish-
ment of the line) in the absence of doxycycline treatment and
identified no mutations associated with potential ‘‘leaky’’ target-
ing at the NGN3 locus (Figure S5E). These findings demonstrate
the versatile use of the iCRISPR platform as an approach
for inducible gene knockout in hPSCs and their differentiated
progeny.
DISCUSSION
Efficient genetic engineering in hPSCs is crucial for elucidating
the genes andmolecular pathways that underlie complex human
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Figure 4. HDR-Mediated Genome Editing
(A) Schematic of Cas9/gRNA and ssDNA oligo targeting sites at the GATA6 locus. A C > T substitution (green) was introduced in the ssDNA HDR template,
generating a new BsgI restriction site (underlined), resulting in an R456C amino acid substitution in GATA6.
(B) Strategy of HDR-mediated genome editing.
(C and D) T7EI and RFLP assay in HUES8 (C) and BJ iPSCs (D) cotransfected with GATA6 gRNA (Cr8) and ssDNA HDR repair template.
(E and F) RFLP analysis (E) and allelic sequence distribution (F) in clones generated with GATA6 gRNA/ssDNA. wt, wild-type; mut, mutation. ‘‘R456C + random
mut’’ includes clones with undesired mutations in addition to the R456C modification in one or both alleles.
(G) Representative sequences of one homozygous (R456C/R456C) and one compound heterozygous (R456C/R456C + additional mutations) GATA6
mutant clone.
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Versatile and Rapid Genome Engineering in hPSCstraits. While recent approaches based on TALEN and CRISPR/
Cas systems have led to encouraging results, a more efficient
and universal platform would be highly desirable for large-scaleCanalysis of gene function in the postgenomic era. The iCRISPR
platform offers a rapid and efficient approach to introduce
mutations in any gene of interest. Based on the high targetingell Stem Cell 15, 215–226, August 7, 2014 ª2014 Elsevier Inc. 221
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Figure 5. Generation of an Allelic Series at
the APOE Locus
(A) Sequence analysis of SNP rs429358 in parental
HUES8 hESCs and BJ hiPSCs lines (ε3/ε3) and
derived HDR-mediated edited clones (ε3/ε4 or
ε4/ε4). Ratios indicate the number of colonies with
the specified genotype out of the total number of
colonies analyzed.
(B) Schematic of Cas9/gRNA and ssDNA oligo tar-
geting sites at the APOE locus. A T(red) > C(blue)
substitution was introduced in the ε4 ssDNA to
convert the ε3 allele into ε4, and in addition, a C > G
substitution (green) was introduced, generating a
novel BanI and disrupting the endogenous NotI
restriction site (underlined). SNP rs429358 and BanI
sites are indicated in APOE exon 4.
(C and D) T7EI and RFLP assay in HUES8 hESCs (C)
and BJ iPSCs (D) cotransfected with APOE gRNA
(Cr3) and ε4 ssDNA HDR repair template. Ratios
indicate the number of colonies with the specified
genotype out of the total number of colonies
analyzed.
See also Figure S4.
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Versatile and Rapid Genome Engineering in hPSCsefficiencies observed in our study, the analysis of 24 colonies
should be sufficient to establish multiple monoallelic and biallelic
mutant lines for loss-of-function studies of a single gene. We
expect that a trained individual could readily perform gRNA
transfection and analyze 300 colonies at a time, enabling the
generation of mutant lines affecting 12 genes in just 1 month,
or 144 genes in a year. Further optimization would enable the
use of the iCRISPR platform for high-throughput genetic analysis
of disease phenotypes in hPSCs. For instance, one may use the
iCRISPR platform to screen an array of human disease-associ-
ated genes for their functional relevance.
Using hESC lines in the current NIH hESC registry (HUES8,
HUES9, and MEL-1) as well as BJ iPSCs, we have generated
multiple iCas9 lines which will be available to the academic
community upon request. Establishing the iCRISPR platform in
different hPSC backgrounds requires minimal efforts due to
the highly efficient TALEN-mediated AAVS1 targeting approach:
only a handful of clonal lines need to be analyzed and the entire
procedure takes around 1 month. Once the system is estab-
lished, it can be used repeatedly and reliably for rapid and
versatile genetic studies in hPSCs, which is highly desirable for
laboratories interested in systematically interrogating biological
and disease mechanisms in isogenic backgrounds. Despite the
stable integration of Cas9 in hPSCs, Cas9 activity is tightly regu-
lated by doxycycline treatment, and no adverse effects were
observed. Two observations support this conclusion: first, the
karyotype of wild-type iCas9 lines remains normal even after222 Cell Stem Cell 15, 215–226, August 7, 2014 ª2014 Elsevier Inc.16 additional passages following line
establishment, and karyotypically normal
mutant lines have been established using
the iCRISPR system (Table S1); second,
even though iCrNGN3 hESCs consti-
tutively express the gRNA targeting the
NGN3 locus, sequencing analysis revealed
no mutations in the targeted site even after
15 additional passages in the absence ofdoxycycline treatment (Figure S5E). Future studies can also
include the option to remove the Cas9 gene when desired by
flanking the Cas9 gene with loxP sites, for example.
It is worth noting that iCRISPR may create complete loss-of-
function (null), partial loss-of-function (hypomorphic), or, less
frequently, gain-of-function (e.g., dominant-negative) alleles.
Studying such allelic series may provide valuable insights into
the molecular basis of distinct phenotypes caused by different
mutations in a single gene, though careful analysis is needed
to determine the exact nature of individual mutant alleles. Recent
studies suggest that the CRISPR/Cas system may have off-
target effects (Cho et al., 2014; Fu et al., 2013; Hsu et al.,
2013; Mali et al., 2013a; Pattanayak et al., 2013), potentially con-
founding genetic studies in hPSCs. Although our analysis so far
has not identified off-target mutations, CRISPR design using
recently developed algorithms can reduce potential off-target ef-
fects (Hsu et al., 2013; Mali et al., 2013b). Characterizing the full
extent of off-target activities in future studies would likely allow
more rational design of gRNAs with higher specificity. To in-
crease target specificity, a double nicking approach has been
developed recently using a nickase version of Cas9 (nCas9)
that requires the cooperation between two gRNAs to create a
DNA DSB (Mali et al., 2013a; Ran et al., 2013a). This strategy
significantly ameliorates, but does not completely eliminate,
off-target activities. We propose two practical solutions to over-
come this limitation for genetic studies in hPSCs. In a first
approach, one may generate independent mutant lines using
Cell Stem Cell
Versatile and Rapid Genome Engineering in hPSCsgRNAs targeting different sequences in the same gene:
observing the same phenotype from multiple independent
mutant lines would strongly suggest that the phenotype is
caused by the disruption of the gene of interest. In a complemen-
tary approach, one may perform rescue experiments using the
iCRISPR platform, which supports highly efficient HDR-medi-
ated scarless correction of mutant sequences.
The iCRISPR platform is also highly versatile. Our platform
allows the generation of hPSCs carrying biallelic mutations in
multiple genes in just 1 month, which will greatly accelerate the
study of complex multigenic interactions that are often chal-
lenging tomodel in vivo due to the random segregation of alleles.
This is highly valuable not only for studying multigenic disorders,
but also for genetic epistasis analysis involving multiple genes.
Additionally, iCRISPR can also be used to introduce specific
nucleotide modifications with high efficiency. This is critical for
dissecting protein functional domains, precisely modeling
human diseases, and potentially correcting disease-associated
mutations for therapeutic intervention. A challenge for modeling
complex diseases lies in the large number of susceptibility loci
that are each associated with multiple sequence variants. For
instance, APOE is associated with three common polymor-
phisms, and it is among the close to 20 LOAD-susceptibility
loci identified so far (Lambert et al., 2013). The iCRISPR platform
offers an ideal solution: it enables the rapid generation of allelic
series, as demonstrated for the APOE locus, and it is expected
to greatly facilitate the perturbation of multiple disease-associ-
ated loci either individually or in combination in isogenic
backgrounds.
Finally, we demonstrate that the CRISPR/Cas system can be
used for inducible gene knockout, which to our knowledge has
not yet been shown in any in vivo or cell culture systems. While
the ubiquitous rtTA expression system used in the present study
only allowed temporal regulation of Cas9 expression, we were
able to achieve tissue-specific regulation by enriching defined
cell populations through FACS. Future studies may also achieve
tissue specificity by expressing rtTA from tissue-specific
promoters. This approach may be further extended to in vivo
systems as a simpler alternative to conventional conditional
knockout strategies, which generally require complex genetic
configurations involving tissue-specific expression of a site-spe-
cific recombinase (e.g., Cre) combined with a conditional allele
(e.g., a ‘‘floxed’’ allele).
In addition to generating mutant alleles with small Indels or
precise nucleotide alterations through NHEJ- or HDR-mediated
repair mechanisms as shown in the present study, the iCRISPR
platform is likely to also greatly facilitate other types of genome
engineering in hPSCs. For instance, iCRISPR may be used to
create larger deletions for study of noncoding RNAs or gene reg-
ulatory regions such as promoters and enhancers. It may also
facilitate the generation of reporter alleles through HDR-medi-
ated gene targeting using long donor DNA templates or defined
chromosomal rearrangements such as translocations. Also,
by swapping Cas9 with other newly developed Cas9 variants
(e.g., nCas9, dCas9, or dCas9-KRAB) (Gilbert et al., 2013; Mali
et al., 2013a; Qi et al., 2013; Ran et al., 2013b), one may repur-
pose iCRISPR for additional tasks such as gene regulation.
Because of the highly efficient TALEN-mediated gene targeting
at the AAVS1 locus and the superior speed, one can easily applyCiCRISPR to any human cell line of interest, including patient-spe-
cific hiPSCs or cancer cell lines. This versatility allows the study
of gene function in practically any hPSC line or genetic back-
ground of choice.
EXPERIMENTAL PROCEDURES
Construction of TALENs,AAVS1 Targeting Vectors, and Cas9/gRNA-
Expressing Vectors
A pair of TALENs (AAVS1-TALEN-L targeting CCCCTCCACCCCACAGT and
AAVS1-TALEN-R targeting TTTCTGTCACCAATCCT) was generated to target
the first intron of the constitutively expressed gene PPP1R12C at the AAVS1
locus (Hockemeyer et al., 2011). The TALEN constructs were constructed
following a published protocol (Sanjana et al., 2012). In brief, a library of
TALE monomers with complementary overhangs was built by PCR using
vector templates from Addgene (32180, 32181, 32182, or 32183). Monomers
were joined into hexamers according to the target DNA sequence. Next, the
hexamers were linked together and incorporated into the full-length TALEN
expression backbone (Addgene 32190).
Neo-M2rtTA donor (Figure S1F) was kindly provided by D. Hockemeyer.
Puro-Cas9 donor (Figure S1E) was constructed by replacing EGFP in
the TRE-TIGHT-EGFP-BW plasmid (Addgene plasmid 22077) (Hockemeyer
et al., 2011) with the human codon-optimized Streptococcus pyogenes
Cas9 cDNA amplified by PCR from pX260 (Addgene plasmid 42229) (Cong
et al., 2013). Puro-Cr donor was generated by introducing a chimeric gRNA
expression cassette, PCR amplified from pX330 (Addgene plasmid 42230)
(Cong et al., 2013), 30 of Cas9 in Puro-Cas9 donor (Figure S5C). piCRct Entry
(Figure S1C), a human codon-optimized S. pyogenes Cas9 expression entry
vector carrying a bicistronic crRNA/tracrRNA duplex expression cassette,
was generated by modifying pX260. piCRg Entry (Figure S1D) was built by de-
leting the bicistronic crRNA/tracrRNA duplex expression cassette from
piCRct Entry and replacing it with the chimeric gRNA expression cassette
PCR amplified from pX330. To generate CRISPR/Cas9 expression vectors
targeting specific genomic loci, 30 or 20 bp of sequence located 50 of the
PAM sequence was cloned in piCRct Entry or piCRg Entry, respectively,
following an established protocol (Cong et al., 2013). Briefly, piCRct Entry
or piCRg Entry were digested with BbsI, dephosphorylated, and gel purified.
A pair of oligos including either 30 or 20 bp homology (Table S4) was an-
nealed and phosphorylated, generating BbsI overhangs that could be cloned
into the BbsI-digested, dephosphorylated vector. Vectors described in this
manuscript will be available to academic researchers through Addgene.
Production of gRNAs through In Vitro Transcription
For production of gRNA, we first generated a T7-gRNA in vitro transcription
(IVT) template by adding the T7 promoter to the gRNA sequence in the piCRg
Entry vector through PCR amplification using CRISPR-specific forward
primers and a universal reverse primer (Table S4).
Alternatively, for APOE gRNAs we designed a 120 nt oligo including the T7
promoter and the full-length gRNA sequence. This oligo was used as a tem-
plate for PCR amplification using T7 and gRNA universal primers (Table S4).
T7-gRNA PCR products were used as templates for IVT using the
MEGAshortscript T7 kit (Life Technologies). The resulting gRNAs were purified
using the MEGAclear kit (Life Technologies), eluted in RNase-free water, and
stored at 80C until use.
gRNA or gRNA + ssDNA Transfection
iCas9 hPSCswere treatedwith doxycycline (2 mg/ml) for 1 or 2 days before and
during transfection. For transfection, cells were dissociated using Accutase
(Stem Cell Technologies) or TrypLE (Life Technologies), replated onto iMEF-
coated plates, and transfected in suspension with gRNAs or gRNA + ssDNA
using Lipofectamine RNAiMAX (Life Technologies) following the manufac-
turer’s instructions. Briefly, gRNA and ssDNA were added at a 10 nM and
20 nM final concentration, respectively, unless otherwise indicated. gRNAs
(or gRNA + ssDNA) and Lipofectamine RNAiMAX were diluted separately in
Opti-MEM (Life Technologies), mixed together, incubated for 5 min at RT,
and added dropwise to cultured hPSCs. A second transfection was performed
24 hr later in some experiments.ell Stem Cell 15, 215–226, August 7, 2014 ª2014 Elsevier Inc. 223
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Off-Target Analysis
Genomic DNA was extracted 2 or 3 days after the last gRNA transfection.
Genomic regions flanking the CRISPR target sites were PCR amplified (Table
S4). For T7EI assays, 12 ml of PCR products were denatured and reannealed
in NEB Buffer 2 (New England Biolabs) in a total volume of 25 ml using
the following protocol: 95C, 5 min; 95C–85C at 2C/s; 85C–25C
at0.1C/s; hold at 4C. Then, 12.5ml of hybridizedPCRproductswere treated
with 5 U of T7EI at 37C for 15min in 13 ml final reaction volume. Products were
then analyzed on 2.5% agarose gels and imaged with a Gel Doc gel imaging
system (Bio-Rad). Quantification was based on relative band intensities using
ImageJ. Indel percentage was determined by the formula 100 3 (1  (1 
(b + c) / (a + b + c))1/2), where a is the integrated intensity of the undigested
PCR product, and b and c are the integrated intensities of each cleavage prod-
uct (Hsu et al., 2013). ForRFLPanalysis, 10ml PCRproductswere digestedwith
enzymes and analyzed on 2.5%agarose gel. Indel percentagewas determined
by the formula 100 3 a / (a + b + c) or 100 3 (b + c) / (a + b + c).
For off-target analysis, ectopic gRNA targets were identified using the rules
outlined in a previous study (Mali et al., 2013b). The most likely off targets fall-
ing in gene coding sequences (four or five sites per gRNA-mediated targeting
experiment) were analyzed through sequencing. Primers for PCR amplification
and sequencing of each off-target site are summarized in Table S4.
Establishment of Knockout or Knockin Lines through NHEJ- or
HDR-Mediated Repair
Two days after the last gRNA or gRNA + ssDNA (Table S4) transfection, hPSCs
were dissociated into single cells and replated at 2,000 cells per 10 cm
dish. Cells were allowed to grow until colonies from single cells became
visible (10 days). Single colonies were randomly picked based on hPSC
morphology, mechanically disaggregated, and replated into individual wells
of 96-well plates. Colonies were amplified, replated as described above, and
analyzed by Sanger sequencing to enable identification of mutant clones.
Clonal cell lines carrying desired mutations were amplified and frozen down.
Alternatively, for APOE experiments, colonies were picked and directly
analyzed by Sanger sequencing to enable the identification of mutant clones.
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